高海拔地区进展期胃癌切除修复交叉互补基因1 mRNA及蛋白表达与化疗疗效的相关性研究

Correlation of ERCC1 mRNA and protein expression in advanced gastric cancer with chemotherapy effect in high-altitude areas

摘要:

目的  研究高海拔地区进展期胃癌切除修复交叉互补基因1（ERCC1）mRNA和蛋白表达，及其与化疗疗效的相关性。方法  逆转录-聚合酶链反应（RT-PCR）检测60例进展期胃癌患者ERCC1 mRNA的表达，免疫组织化学法检测ERCC1蛋白的表达并予以FOLFOX4方案化疗，分析ERCC1 mRNA及蛋白表达与化疗客观反应率（ORR）和无进展生存期（PFS）的相关性。结果  进展期胃癌ERCC1 mRNA的表达与化疗疗效（ORR）、PFS呈负相关（P =0.038和0.032）；ERCC1蛋白表达与FOLFOX4化疗疗效（ORR）无关（P =
0.089），与PFS呈负相关（P =0.039）。结论  高海拔地区，进展期胃癌ERCC1 mRNA与化疗疗效呈负相关，ERCC1蛋白表达与化疗疗效无关；ERCC1 mRNA及蛋白表达与PFS呈负相关。

Abstract:

Objective To investigate the values of mRNA and protein of excision repair cross-complementation group 1 (ERCC1) in predicting the prognosis of advanced gastric cancer patients treated with FOLFOX4 regime in high-altitude areas. Methods Seventy patients with advanced gastric cancer were enrolled in this study, 60 patients were eligible for analysis. All patients received FOLFOX4 regime repeated every two cycles. RT-PCR was used for analysis of ERCC1 mRNA; immunohistochemistry was used for analysis of ERCC1 protein expression. The relationships of mRNA and protein of ERCC1 with objective response rate (ORR) and progression-free survival (PFS) time were analyzed. Results ERCC1 mRNA expression was negatively associated with objective response rate (P = 0.038) and progression-free survival (P = 0.032). ERCC1 protein expression was not correlated with ORR of FOLFOX4 treatment (P = 0.089), but was negatively correlated with PFS (P = 0.039). Conclusions In high-altitude areas, the expression of ERCC1 mRNA in advanced gastric cancer patients is negatively correlated with PFS and ORR of FOLFOX4 treatment; the expression of ERCC1 protein is not associated with ORR, but has correlation with PFS in advanced gastric cancer patients.